Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-067 manufacturers

Filters

Filters

Filters , active

Country of origin : Japan

Clear all

None products found

pp-067

Tablets

Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
GMP approvals
Japan
Comments
Indication: Advanced or metastatic osteosarcoma and other solid tumors in patients who have progressed after standard treatments. Clinical stage: Phase III in osteosarcoma, with additional early-phase studies in multiple solid tumor indications. Modality: Small-molecule oral therapy. Mechanism / Target: Multi-kinase inhibition of FLT3, MET, AXL and related pathways that drive tumor growth, angiogenesis, and survival. Route / form: Oral tablets. Differentiation: Broad multi-target profile designed to overcome resistance to single-target TKIs, offering dual effects on tumor proliferation and angiogenesis with potential applicability across diverse solid tumors.
Manufacturer #38605

A research-driven pharma company developing therapies across oncology and other major diseases. It advances innovative medicines through global R&D and strategic alliances. The organization emphasizes high-quality manufacturing and patient impact.

 

 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.